New Leaf Venture Partners

New Leaf Venture Partners is a prominent venture capital firm based in New York City, specializing in investments within the healthcare technology sector. Established with a deep focus on life sciences, the firm targets companies developing breakthrough products and technologies that address significant unmet medical needs across therapeutics, medical devices, diagnostics, and digital health. With a long-standing history in the venture capital landscape, New Leaf Venture Partners has built a reputation for leveraging its team's extensive scientific, medical, and operational expertise to identify and nurture high-potential healthcare innovations.

The firm's investment strategy typically focuses on growth-stage companies, primarily participating in Series A, Series B, and Series C rounds. New Leaf Venture Partners seeks to partner with entrepreneurial teams, providing not only capital but also strategic guidance and industry connections to accelerate the development and commercialization of their portfolio companies. Their approach emphasizes a rigorous due diligence process and a hands-on partnership model, aiming to support companies from early development through clinical trials and market entry.

New Leaf Venture Partners manages substantial capital, with approximately $1.85 billion in assets under management across five dedicated funds, including their most recent New Leaf Ventures V, L.P. fund raised in 2022. This significant capital base enables them to make meaningful investments and provide follow-on funding to support their portfolio companies' long-term growth. The firm has demonstrated a prolific investment pace, having made 121 investments to date, and has frequently taken a leadership role, acting as a lead investor 36 times. While specific initial check sizes can vary based on the stage and capital requirements of the company, New Leaf Venture Partners typically deploys first checks ranging from $5 million to $25 million, reflecting their capacity to support substantial financing rounds in the capital-intensive healthcare industry.